| __timestamp | Alnylam Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 5699000000 |
| Thursday, January 1, 2015 | 60610000 | 5001000000 |
| Friday, January 1, 2016 | 89354000 | 5002000000 |
| Sunday, January 1, 2017 | 199365000 | 4849000000 |
| Monday, January 1, 2018 | 382359000 | 4551000000 |
| Tuesday, January 1, 2019 | 479005000 | 4871000000 |
| Wednesday, January 1, 2020 | 588420000 | 7661000000 |
| Friday, January 1, 2021 | 620639000 | 7690000000 |
| Saturday, January 1, 2022 | 770658000 | 7814000000 |
| Sunday, January 1, 2023 | 795646000 | 7772000000 |
Infusing magic into the data realm
In the ever-evolving landscape of the biopharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outspent Alnylam, with SG&A expenses peaking at approximately $7.8 billion in 2022, a 40% increase from 2014. In contrast, Alnylam's expenses grew more dramatically, surging by over 1,600% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. This stark contrast highlights the differing operational scales and strategic priorities of these two industry players. As Bristol-Myers Squibb maintains its robust market presence, Alnylam's rapid growth trajectory underscores its rising influence in the biopharma sector.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Wave Life Sciences Ltd.